Cathay International Holdings Limited ("CIH"), focused on the People's Republic of China, is an investment holding company and a leading investor in the growing healthcare sector in China. The Group employs more than 2000 people across China, including over 30 specialist corporate and business development staff based at Hong Kong and Shenzhen offices.

The Group aims to identify high growth investment opportunities in the healthcare markets in China and build them into market sector leaders, with a clear exit strategy. The Group has demonstrated a strong track record of identifying potential high-growth investment opportunities in the healthcare sector, including: Lansen Group, a leading specialty pharmaceutical company focused on rheumatology and Haotian Group, a company engaged in the manufacture, marketing and sale of key active ingredients for healthcare products, including inositol. To complement its healthcare portfolio, CIH has an R&D business focused on bringing new products to the growing Chinese market.

The Group also has a private equity investment arm focused on minority investment opportunities and a hotel investment.